Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB18 in Patients With Tumor Cachexia
NCT07519564Phase 1Recruiting
- Sponsor
- Kexing Biopharm
- Start
- Jun 2026
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GB18-06 in cachexia (3 arms), sponsored by Kexing Biopharm. Primary endpoint: Incidence of adverse events at 24 weeks. Started Jun 2026; status: recruiting.
02
Drugs
GB18-06
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT07519564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07519564.